Literature DB >> 21192882

Crimean-Congo hemorrhagic fever virus, northeastern Greece.

Anna Papa, Evangelia Tzala, Helena C Maltezou.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21192882      PMCID: PMC3204620          DOI: 10.3201/eid1701.100073

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Crimean-Congo hemorrhagic fever virus (CCHFV) causes a disease in humans that is characterized by fever and hemorrhagic manifestations, with death rates up to 30%. Humans are infected through tick bites or contact with the viremic blood of patients or livestock. CCHFV belongs to the genus Nairovirus (family Bunyaviridae), which contains 7 serogroups: CCHFV, Dugbe virus, Hughes virus, Sakhalin virus, Dera Ghazi Khan virus, Qalyub virus, and Thiafora virus. A CCHFV strain, AP92, was isolated from Rhipicephalus bursa ticks collected in 1975 from goats in Vergina, a village in northern Greece (). Seroprevalence among Vergina residents was 6.1% (). During 1981–1988, the seroprevalence among 3,388 persons in Greece was 1.1% (range 0%–9.6%) (). The first Crimean-Congo hemorrhagic fever case in Greece was reported in 2008, when a woman died in Komotini in northeastern Greece (). The causative strain (Rodopi) differs from strain AP92 (). To determine the prevalence of CCHFV antibodies in the human population of northeastern Greece, serum samples were collected prospectively during November 2008–April 2009 from 1,178 residents of Drama, Kavala, Xanthi, Rodopi, and Evros prefectures. A predefined number of participants were enrolled in the study on the basis of prefecture population. Participants were selected randomly among persons who were referred to health care settings for blood testing, regardless of reason for testing, and regardless of CCHFV risk factors. Oral consent was given by all participants. A questionnaire was completed concerning age, sex, occupation, place of residence, history of tick bite, symptoms after the bite, contact with animals, and any other situation related with increased risk for tick bite. All age groups were included (range 0–97 years, mean ± SE age 53.2 ± 0.63). Serum samples were tested for CCHFV immunoglobulin (Ig) G by ELISA (Vektor-Best, Koltsovo, Novosibirsk, Russia). The data were analyzed by using Stata Special Edition 9 (StataCorp LP, College Station, TX, USA). Multivariate logistic regression modeling was adopted to identify potential risk factors for acquisition of CCHFV infection. Odds ratios (ORs) with 95% confidence intervals (CIs) were obtained. p values <0.05 were considered significant. In total, 37 (3.14%) of 1,178 persons were positive for CCHFV by IgG. The mean ± SE age of seropositive and seronegative persons was 68.7 ± 2.54 years (range 0–87 years) and 55.6 ± 0.79 years (range 0–97 years). The female:male ratio was 1.6 among tested persons and 0.6 among seropositive persons. Seroprevalence differed among prefectures: Rodopi, where the fatal Crimean-Congo hemorrhagic fever case was observed, and Evros had the highest values (4.95% and 4.49%), Drama and Xanthi the lowest (1.34% and 1.09%), and no IgG-positive person was found in Kavala. The distribution of regions where IgG-positive persons were found is presented in the Figure. Seropositive persons lived in rural areas at an altitude of 10m to 270 m; however, this factor was not significant (p = 0.358). Crude analysis showed that age, sex, prefecture, occupation, contact with goats and sheep, slaughtering, and history of tick bite were significantly associated with seropositivity. Multivariate analysis showed that the following variables were significant risk factors for acquisition of CCHFV infection: age (OR 1.05, 95% CI 1.02–1.08; p = 0.002), residence in Rodopi prefecture (with Drama prefecture as reference category) (OR 6.55, 95% CI 1.36–31.60; p = 0.019), contact with goats (OR 3.40, 95% CI 1.22–9.43; p = 0.019), history of slaughtering (OR 2.53, 95% CI 1.01–6.45; p = 0.048), and history of tick bite (OR 2.51, 95% CI 1.03–6.15; p = 0.044). When we compared our results with those of Antoniadis et al. (), marked differences were seen: seroprevalence in Rodopi, Evros, Xanthi, and Drama was 0.5%, 0%, 1.2%, and 0%, respectively, compared with 4.95%, 4.49%, 1.09%, and 1.34% in the present study, which suggests that during the past 20 years CCHFV was introduced in some areas in Greece or increased its circulation in others. Climatic and environmental changes and infested livestock movements (legal or illegal) in a habitat suitable for ticks might play a role in the current situation (). Further studies are necessary to estimate the seroprevalence in the whole country and detect disease-endemic foci of the disease. In addition, surveys for CCHFV in Ixodid ticks are necessary to enable the construction of risk maps and risk assessment analysis. Five prefectures in northeastern Greece (inset), showing locations of persons who were immunoglobulin G–positive for Crimean-Congo hemorrhagic fever virus (solid circles), 2008–2009. Size of circle indicates number of persons with positive test results in each location.
  4 in total

1.  Crimean-Congo hemorrhagic fever in Greece: a public health perspective.

Authors:  Helen C Maltezou; Anna Papa; Sotirios Tsiodras; Vasiliki Dalla; Efstratios Maltezos; Antonios Antoniadis
Journal:  Int J Infect Dis       Date:  2009-01-19       Impact factor: 3.623

2.  A case of Crimean-Congo haemorrhagic fever in Greece, June 2008.

Authors:  A Papa; H C Maltezou; S Tsiodras; V G Dalla; T Papadimitriou; I Pierroutsakos; G N Kartalis; A Antoniadis
Journal:  Euro Surveill       Date:  2008-08-14

3.  Emergence of Crimean-Congo haemorrhagic fever in Greece.

Authors:  A Papa; V Dalla; E Papadimitriou; G N Kartalis; A Antoniadis
Journal:  Clin Microbiol Infect       Date:  2009-10-19       Impact factor: 8.067

4.  Serological evidence of human infection with Congo-Crimean hemorrhagic fever virus in Greece.

Authors:  A Antoniadis; J Casals
Journal:  Am J Trop Med Hyg       Date:  1982-09       Impact factor: 2.345

  4 in total
  11 in total

Review 1.  Immunobiology of Crimean-Congo hemorrhagic fever.

Authors:  Sergio E Rodriguez; David W Hawman; Teresa E Sorvillo; T Justin O'Neal; Brian H Bird; Luis L Rodriguez; Éric Bergeron; Stuart T Nichol; Joel M Montgomery; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2022-01-11       Impact factor: 10.103

2.  Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk.

Authors:  Raquel Rodrigues; Gláucia Paranhos-Baccalà; Guy Vernet; Christophe N Peyrefitte
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

3.  Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment.

Authors:  Helena C Maltezou; Anna Papa
Journal:  BMC Med       Date:  2011-12-08       Impact factor: 8.775

4.  Sensitive and specific detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV)-Specific IgM and IgG antibodies in human sera using recombinant CCHFV nucleoprotein as antigen in μ-capture and IgG immune complex (IC) ELISA tests.

Authors:  Petra Emmerich; Angela Mika; Ronald von Possel; Anne Rackow; Yang Liu; Herbert Schmitz; Stephan Günther; Kurtesh Sherifi; Barie Halili; Xhevat Jakupi; Lindita Berisha; Salih Ahmeti; Christina Deschermeier
Journal:  PLoS Negl Trop Dis       Date:  2018-03-26

5.  Crimean-Congo Hemorrhagic Fever Virus and Borrelia burgdorferi sensu lato in Ticks from Kosovo and Albania.

Authors:  Kurtesh Sherifi; Agim Rexhepi; Kristaq Berxholi; Blerta Mehmedi; Rreze M Gecaj; Zamira Hoxha; Anja Joachim; Georg G Duscher
Journal:  Front Vet Sci       Date:  2018-03-06

6.  Spatial cluster analysis of Crimean-Congo hemorrhagic fever virus seroprevalence in humans, Greece.

Authors:  Anna Papa; Persefoni Sidira; Antreas Tsatsaris
Journal:  Parasite Epidemiol Control       Date:  2016-08-05

7.  Determination of Seroprevalence and Risk Factors of Crimean-Congo Haemorrhagic Fever (CCHF) in the Endemic Region in Turkey: A Population-Based Cross-Sectional Study.

Authors:  Rıza Çıtıl; Mücahit Eğri; Yalçın Önder; Fazilet Duygu; Yunus Emre Bulut; Özkan Yaşayancan; Nagehan Yıldız Çeltek; Şafak Şahin
Journal:  J Trop Med       Date:  2021-05-17

8.  Diagnostic assays for Crimean-Congo hemorrhagic fever.

Authors:  Jessica Vanhomwegen; Maria João Alves; Tatjana Avšič Zupanc; Silvia Bino; Sadegh Chinikar; Helen Karlberg; Gülay Korukluoğlu; Miša Korva; Masoud Mardani; Ali Mirazimi; Mehrdad Mousavi; Anna Papa; Ana Saksida; Batool Sharifi-Mood; Persofoni Sidira; Katerina Tsergouli; Roman Wölfel; Hervé Zeller; Philippe Dubois
Journal:  Emerg Infect Dis       Date:  2012-12       Impact factor: 6.883

9.  Crimean-Congo hemorrhagic fever virus, Greece.

Authors:  Anna Papa; Persefoni Sidira; Victor Larichev; Ludmila Gavrilova; Ksenia Kuzmina; Mehrdad Mousavi-Jazi; Ali Mirazimi; Ute Ströher; Stuart Nichol
Journal:  Emerg Infect Dis       Date:  2014-02       Impact factor: 6.883

10.  Bayesian phylogeography of Crimean-Congo hemorrhagic fever virus in Europe.

Authors:  Gianguglielmo Zehender; Erika Ebranati; Renata Shkjezi; Anna Papa; Camilla Luzzago; Elena Gabanelli; Alessandra Lo Presti; Alessia Lai; Giovanni Rezza; Massimo Galli; Silvia Bino; Massimo Ciccozzi
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.